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Abstract  
Background 
The purpose of this multistage, adaptively, designed randomized phase II study 
was to evaluate the role of intraperitoneal (IP) chemotherapy following neoadjuvant 
chemotherapy (NACT) and optimal debulking surgery in women with epithelial ovarian 
cancer (EOC).   
Patients and Methods 
We performed a multicentre, 2 stage, phase II trial. Eligible patients with stage 
IIB-IVA EOC treated with platinum-based intravenous (IV) NACT followed by optimal 
(<1cm) debulking surgery were randomized to one of 3 treatment arms: 1) IV 
carboplatin/paclitaxel; 2) IP cisplatin plus IV/IP paclitaxel, or 3) IP carboplatin plus IV/IP 
paclitaxel. The primary endpoint was 9 month progressive disease rate (PD9). 
Secondary endpoints included progression free survival (PFS), overall survival (OS), 
toxicity and quality of life (QOL).  
Results 
Between 2009 and 2015, 275 patients were randomized. IP cisplatin containing 
arm did not progress beyond the first stage of the study after failing to meet the pre-set 
superiority rule. The final analysis compared IV carboplatin/ paclitaxel (n=101) to IP 
carboplatin, IV/IP paclitaxel (n=102). The intention to treat PD9 was lower in the IP 
carboplatin arm compared to the IV carboplatin arm:  24.5% (95% CI 16.2%-32.9%) vs. 
38.6% (95% CI 29.1%- 48.1%) p=0.065. The study was underpowered to detect 
differences in PFS: HR PFS 0.82 (95% CI 0.57 - 1.17); p=0.27 and OS HR 0.80 (95% 
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CI 0.47-1.35) p=0.40. The IP carboplatin based regimen was well tolerated with no 
reduction in QOL or increase in toxicity compared to IV administration alone. 
Conclusion 
In women with stage IIIC or IVA EOC treated with NACT and optimal debulking 
surgery, IP carboplatin based chemotherapy is well tolerated and associated with an 
improved PD9  compared to IV carboplatin based chemotherapy.   
clinicaltrials.gov, NCT01622543 
 
Key words: 
IP chemotherapy, ovarian cancer, neoadjuvant 
 
 
 
  
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdx754/4654091
by ESMO Member Access user
on 06 December 2017
5 
Introduction  
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic 
malignancy in the developed world with the majority of women presenting with stage 
III/IV disease1. The peritoneal cavity is the principal site of disease and intraperitoneal 
(IP) chemotherapy has been investigated as a means of increasing the dose intensity 
delivered to the tumor2. At the time OV21/PETROC was conceived, three randomized 
clinical trials (RCTs) and a meta-analysis had demonstrated improved survival for 
women with stage III EOC who received a combination of intravenous (IV) and IP 
chemotherapy following optimal, primary debulking surgery3-5. An update of the most 
recent of these trials, GOG 172, confirmed a continued benefit for women who had 
received the experimental arm6. IP/IV chemotherapy, however, remains controversial7. 
Debate has centred on the impact of drug scheduling on the IP benefits and  concerns 
over the toxicity of IP cisplatin, used in the positive studies, compared to IV carboplatin8. 
The use of neoadjuvant chemotherapy (NACT) prior to a definitive debulking 
attempt is increasingly used in advanced EOC9,10 based on two RCTs which 
demonstrated non-inferiority and lower peri-operative morbidity compared to primary 
surgery followed by chemotherapy11,12. None of the IP/IV RCTs included patients who 
had undergone optimal debulking surgery following NACT.  
OV21/PETROC investigated the hypothesis that women undergoing NACT 
followed by optimal debulking surgery would benefit from IV/IP chemotherapy. 
 
Patients and Methods  
Patients 
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Patients were eligible if they had histologically confirmed EOC, primary peritoneal 
or fallopian tube carcinoma, were FIGO13 stage IIB-IVA (pleural effusion only) at initial 
diagnosis, had undergone 3 or 4 cycles of platinum based NACT followed (within 6 
weeks) by optimal (≤1cm) debulking surgery and had an ECOG performance status of 
0-2. Exclusion criteria included: mucinous or borderline histology, extensive intra-
abdominal adhesions, bowel obstruction or unresolved > grade 2 peripheral neuropathy.  
Trial Design 
OV21/PETROC was a Gynecologic Cancer Intergroup (GCIG) study developed 
by the Canadian Clinical Trials Group (CCTG) in collaboration with the National Cancer 
Research Institute (UK) and was approved by institutional ethics boards of participating 
institutions. OV21/PETROC was a randomized multistage study. The initial stage of the 
study was designed to “pick the winner” of two IP chemotherapy regimens to carry 
forward into a two-arm (IV vs. IP) phase III comparison with progression free survival 
(PFS) as the primary outcome. However, due to poor accrual and following Independent 
Data Monitoring Committee review, the design was subsequently amended to an 
expanded two-arm phase II study using the primary outcome measure of PD9, defined 
as the proportion of patients with disease progression or death due to any cause 
occurring within 9 months of randomization (Figure 1).  
Protocol Therapy  
Randomization was permitted intraoperatively or within 6 weeks of debulking 
surgery using a central, web-based minimization procedure with the following 
stratification factors: Cooperative Group, reason for NACT (unresectable disease vs. 
other), residual disease (macroscopic vs. microscopic), and timing of IP catheter 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdx754/4654091
by ESMO Member Access user
on 06 December 2017
7 
placement (intraoperatively or post-operatively by interventional radiology) (see IR - 
Appendix protocol for details). 
Protocol chemotherapy was administered every 21 days for 3 cycles. Stage I 
patients were randomized 1:1:1 to Arm 1: paclitaxel 135 mg/m2 IV and carboplatin area 
under the curve (AUC) 5/6 IV on day 1 with  paclitaxel 60 mg/m2 IV on day 8; Arm 2: 
paclitaxel 135 mg/m2 IV  and cisplatin 75 mg/m2 IP on day 1, with paclitaxel 60 mg/m2 
IP on day 8; or Arm 3: paclitaxel 135 mg/m2 IV and carboplatin AUC 5/6 IP day 1, with 
paclitaxel 60 mg/m2 IP on day 8. Subsequent to stage I, patients were randomized 1:1 
to the IV arm (Arm 1) and the remaining IP arm. Carboplatin dosing was AUC 5 if a 
measured glomerular filtration rate (GFR) was available and AUC 6 if an estimated GFR 
was used. Doses were adjusted for grade 3 adverse events (AEs) (≥ grade 2 for 
neurotoxicity); while grade 4 AEs or ≥ grade 3 neurotoxicity led to drug discontinuation. 
Patients not tolerating IP chemotherapy were offered institutional standard IV 
chemotherapy. 
 
Assessments and Outcome Measures  
The primary endpoint for the study was PD9 rate. Disease progression was 
defined using RECIST V1.1 and/or GCIG CA125 criteria14,15. Secondary endpoints 
included PFS, OS, feasibility, safety and quality of life (QOL) assessed using 
questionnaires EORTC QLQ-C3016, EORTC QLQ-OV2817,18 and FACT/GOG-Ntx19. AEs 
were coded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0.  
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Physical examination, biochemistry and CA125 were assessed on day 1 of each 
cycle and complete blood count on days1, 8 and 15. Imaging studies were done at the 
end of treatment; every 6 months for 2 years and then as clinically indicated. Patients 
were reviewed (physical examination, CA125) post treatment at 6 weeks, every 3 
months for 2 years, every 6 months years 2-4 then annually until death. QOL 
instruments were collected at 3, 6 and 12 months then annually. 
 
Statistical Methods  
 
First Stage  
After the first 50 patients randomized to each arm had a minimum 9-month 
follow-up, an independent Data Safety Monitoring Committee (DSMC) reviewed PD9, 
compliance, and safety to determine if the trial should continue to the second stage. An 
IP arm would be considered as futile to continue if its PD9 was 5% or greater than that 
of the IV arm, which had an expected PD9 of 40% (based on results of a previous front-
line randomized study20 adjusted for the randomization timing in OV21/PETROC after 
NACT). If neither IP arm met criteria for futility, the arm with lower PD9 would be 
selected for the second stage unless ≥ 29 patients failed to complete that IP treatment 
due to toxicity.  
Second Stage  
A sample size of 200 in the second stage, including patients accrued in Stage I, 
permitted detection of a 19% difference in PD9 between Arms 1 (assumed to be 40%) 
and the selected IP arm (Arm 3) with 80% power at two-sided 0.05 level. This absolute 
difference was considered relevant based on PD9 data extrapolated from GOG1724. 
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The final analysis of both intention to treat (ITT- as randomized) and per protocol 
(eligible, received at least one dose of protocol treatment, not lost to follow-up or 
consent withdrawal) populations was performed once all patients had 9-month follow-
up. A stratified Cochran-Mantel-Haenszel (CMH) test adjusting for stratification factors 
at randomization was the primary method used to compare PD9 between the two 
treatment arms. Odds ratio and associated 95% confidence interval were obtained from 
stratified logistical regression models. PFS and OS were summarized using Kaplan-
Meier plots and compared using the stratified log rank test. Estimates of the relative 
treatment differences were obtained from hazard ratios (HRs) and 95% CIs from 
stratified Cox regression models.  
Analyses of QOL data using previously described methodology21,22, were 
restricted to patients who had a baseline and at least one assessment on study. Chi-
square test was used to compare the distributions of response categories between 
arms.  
Safety was evaluated in patients who received at least one dose of protocol 
therapy. 
 
Results  
Patients and Protocol Treatment Received 
Between September 2009 and May 2015, 275 patients were randomized: 101 in 
Arm 1(IV alone), 72 in Arm 2 (IP cisplatin based regimen) and 102 in Arm 3 (IP 
carboplatin based regimen). 254 patients received at least one dose of protocol therapy 
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(Figure 1). 72 patients were accrued to Arm 2 since accrual was not halted while 
awaiting Stage I outcomes.  
Baseline characteristics by treatment arm are presented in Table 1. The three 
groups were well balanced and the median time from diagnosis to randomization was 3 
months. The majority of participants (72.8 %) underwent intraoperative randomization.  
Most patients (88% Arm 1, 72% Arm 2, and 76% Arm 3) were able to complete 
three cycles of chemotherapy. Seven IP patients crossed over to IV chemotherapy (3 in 
Arm 2 and 4 in Arm 3). 
 
Efficacy 
First Stage 
Stage 1 analysis included 51 patients on each arm. The PD9 at this time was 
37.3% on Arm 1, 45.1% on Arm 2, and 27.5% on Arm 3. As per the statistical plan, Arm 
2 accrual was discontinued. Follow-up was maintained on all patients until the final 
analysis.  
Second Stage 
A total of 203 patients were enrolled in Arms 1 and 3.  As shown in Table 2, for 
the ITT population, the PD9 was 38.6% (95% CI 29.1 to 48.1) in Arm 1 (IV), and 24.5% 
(95% CI 16.2 to 32.9) in Arm 3 (IP carboplatin), p = 0.065. For the per protocol 
population analysis, the PD9 was 42.2%, (95% CI 31.9 to 53.1) Arm 1 and 23.3%, (95% 
CI 15.1 to 33.4) Arm 3, p= 0.03. 
At the time of data cut off (February 28, 2016) the median follow-up was 33 
months. The median PFS was 11.3 months in Arm 1 and 12.5 months in Arm 3 (Figure 
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2) with a hazard ratio of 0.82 95% CI (0.57 to 1.17).  The 2-year OS was 74.4% in Arm 
1, and 80.6% in Arm 3 (Figure 3), HR 0.80, 95% CI (0.47 to 1.35) (Figure 3). 
Adverse Events 
Severe treatment related (≥ grade 3) AEs during protocol therapy occurred in 
23% of patients in Arm 1, 22% in Arm 2, and 16% Arm 3 (p=NS, details in Supplemental 
Table 1). The most common severe AEs (≥ 5% in at least one treatment arms) were 
febrile neutropenia (Arm 1: 5.3%, Arm 2: 1.5%, Arm 3: 1.1%) and abdominal pain (Arm 
1: 1.1%, Arm 2: 6.0%, Arm 3: 1.1%). Catheter-related complications, obstruction being 
the most common, led to treatment discontinuation in 8 (11.9%) patients in Arm 2 and 7 
(7.6%) in Arm 3.  
Quality of Life 
Compliance with QOL assessment was 87% at baseline and 80% at 6 months 
across arms. No statistically significant difference between arms was found on any 
scale. In particular, no differences were seen in peripheral neuropathy or 
gastrointestinal symptoms scales at baseline or in follow-up between all arms. 
Significant improvements in gastrointestinal functioning over time were seen in all arms 
(see detailed QOL response by treatment arm in Supplemental Figure 1).  
 
Discussion  
OV21/PETROC was designed to answer two clinically important questions: The 
role of IP/IV chemotherapy in the NACT patient population and to provide RCT data on 
an IP carboplatin-based regimen. The study demonstrates that IP/IV chemotherapy is 
safe and well tolerated in this patient population with no detriment to QOL. Whilst 
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delivery of IP/IV chemotherapy was associated with an 17.7% improvement in the PD9 
(ITT) (18.9% improvement, per protocol treatment), similar to that extrapolated from 
GOG 1724, the trial is underpowered to draw firm conclusions about PFS and OS. 
OV21/PETROC provides data for discussion with patients around the use of IP 
carboplatin based regimens which have, in some cases, been adopted in the 
community without RCT data7.    
OV21/PETROC had a novel, adaptive, 2 stage design. The PD9, post 
randomization, endpoint was selected as a surrogate measure of efficacy to allow for a 
seamless transition into the second stage of the trial. To avoid the criticism levelled at 
previous studies the regimens included in the trial were balanced for both schedule and 
dose of paclitaxel and carboplatin8.  As a result, the IV reference arm (with day 8 
paclitaxel) was not a previously reported, standard of care. However, the observed PD9 
of 42.2% is reassuringly consistent with the (40%) rate observed for the IV arm in our 
previous study20. At the end of the first stage of this trial, Arm 2 (IP cisplatin) was 
discontinued due to lack of efficacy compared to the IV regimen. The prior positive, 
frontline IP RCTs investigated regimens containing IP cisplatin 100 mg/m2 3-5. Our use 
of a lower dose (cisplatin 75 mg/m2) was based on concerns over toxicity at 100mg/m2 
and this may have impacted efficacy. These data plus the initial findings of GOG 252, 
that also show no benefit for IP cisplatin at 75mg/m2 24, do not support using 75mg/m2 
cisplatin IP in practice.  
A major limitation of OV21/PETROC was the revision of the statistical design for 
the second stage of the trial. The independent DSMC were asked to make a 
recommendation, based on the study’s potential to provide clinically useful information, 
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to either stop the trial or to continue with a limited expansion into the 2-arm stage. 
Whilst acknowledging that PD9 represented an unconventional endpoint, the DSMC 
recommended amending the protocol. In addition, the comparison of IP and IV 
carboplatin based regimens provides additional data on QOL and toxicity. Further data 
on the upfront use of IP carboplatin (alone) is awaited from the JGOG iPocc study and 
survival analysis of GOG 252 which also investigated an IP carboplatin arm23.   
Placing the OV21/PETROC data in the context of other NACT studies is 
challenging given that study entry/randomization was at the time of debulking surgery. 
However, in over 80% of cases the decision to select NACT was inoperable disease 
with over 90% having stage IIIC-IV disease. This aligns with entry requirements for 
other NACT studies11,12. Median OS (from randomization) observed in OV21/PETROC 
(microscopic and < 1cm) was 38.1 months in the IV arm and 59.3 months for the IP/IV 
arm. Making a conservative presumption of 10 weeks from date of first pre-operative 
chemotherapy to randomization (3 cycles of chemotherapy and median 4-week time 
interval to surgery in OV21/PETROC) that would translate into an OS from diagnosis of 
40.6 months in the IV arm and 61.8 months in the IP/IV arm. Whilst the comparison is 
crude, the IV arm of OV21/PETROC does appear to be performing in a similar range to 
the other NACT studies.  These earlier studies would, however have included patients 
with a poorer prognosis as all patient in OV.21-PETROC underwent surgery whilst in 
the other trials, patients were entered at diagnosis and some progressed prior to NACT. 
The IP arm is certainly no worse than the IV arm and, had the study been completed as 
originally intended, raises the intriguing possibility that it may have been better.  
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdx754/4654091
by ESMO Member Access user
on 06 December 2017
14 
Interpretation of the clinical relevance of OV21/PETROC is limited by the lack of 
power to detect changes in PFS and OS. IP chemotherapy remains controversial. 
OV21/PETROC does, however, provide RCT data both to support the use of IP 
carboplatin, and to inform clinicians and patients when making choices about 
subsequent therapy following NACT and optimal debulking surgery. Correlative studies 
are planned to identify potential predictive biomarkers and inform the design of future 
clinical trials. 
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Figure Legends 
Figure 1:  OV21/PETROC Flow Diagram  
Figure 2:  PFS Arm 1: IV carboplatin + IV paclitaxel; Arm 2: IP cisplatin + IV/IP 
paclitaxel; Arm 3: IP carboplatin + IV/IP paclitaxel 
 
Figure 3:  Overall Survival - Arm 1: IV carboplatin + IV paclitaxel; Arm 2: IP cisplatin 
+ IV/IP paclitaxel; Arm 3: IP carboplatin + IV/IP paclitaxel 
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Table 1: Characteristics of Patients and Treatments 
 Arm 1 
(N=101) 
IV carboplatin 
 + IV paclitaxel 
Arm 2 
(N=72) 
IP cisplatin  
+ IV/IP paclitaxel 
Arm 3 
(N=102) 
IP carboplatin 
 + IV/IP paclitaxel 
Total 
(N=275) 
Age     
Median (range), years  62 (33-83)  61 (29-78)  62 (40-82)  62 (29-83) 
≤ 65  65 (64.4)  52 (72.2)  71 (69.6)  188 (68.4) 
> 65  36 (35.6)  20 (27.8)  31 (30.4)  87 (31.6) 
Race or ethnic group     
White  92 (91.1)  67 (93.1)  95 (93.1)  254 (92.4) 
Black or African American  1   (1.0)  1   (1.4)  1   (1.0)  3   (1.1) 
Asian  5   (5.0)  1   (1.4)  4   (3.9)  10  (3.6) 
Other  3   (3.0)  3   (4.2)  2   (2.0)  8  (2.9) 
ECOG performance status     
0  46 (45.5)  41 (56.9)  49 (48.0)  136 (49.5) 
1  53 (52.5)  29 (40.3)  47 (46.1)  129 (46.9) 
2  2   (2.0)  2   (2.8)  6   (5.9)  10   (3.6) 
Primary site     
Ovary  75 (74.3)  55 (76.4)  73 (71.6)  203 (73.8) 
Peritoneal  17 (16.8)  16 (22.2)  20 (19.6)  53 (19.3) 
Fallopian tube  6   (5.9)  1   (1.4)  7   (6.9)  14   (5.1) 
Other or unknown  3   (3.0)  0   (0.0)  2   (2.0)  5   (1.0) 
Histologic type     
Serous adenocarcinoma  95 (94.1)  69 (95.8)  95 (93.1)  259 (94.2) 
Adenocarcinoma, unspecified   3   (3.0)  2   (2.8)  3   (2.9)  8   (2.9) 
Other or unknown  3   (3.0)  1   (1.4)  4   (3.9)  8   (2.9) 
Histologic grade     
Poorly differentiated or undifferentiated (III)  91 (90.1)  65 (90.3)  96 (94.1)  252 (91.6) 
Intermediate differentiation (II)  3   (3.0)  5   (6.9)  3   (2.9)  11   (4.0) 
Unknown  7   (6.9)  2   (2.8)  3   (2.9)  12   (4.4) 
Months from histologic diagnosis to 
randomization 
    
  Median (range)  3.0 (0-4.7)  2.8 (0-5.9)  3.2 (0-5.3)  3.0 (0-5.9) 
Stage at initial diagnosis     
IIB  1   (1.0)  0   (0.0)  0   (0.0)  1   (0.4) 
IIC  0   (0.0)  1   (1.4)  1   (1.0)  2   (0.7) 
IIIB  6   (5.9)  0   (0.0)  6   (5.9)  12   (4.4) 
IIIC  82 (81.2)  61 (84.7)  82 (80.4)  225 (81.8) 
Iva  12 (11.9)  10 (13.9)  13 (12.7)  35 (12.7) 
Reason for NACT before debulking surgery     
Unresectable disease  85 (84.2)  61 (84.7)  84 (82.4)  230 (83.6) 
Other  16 (15.8)  11 (15.3)  18 (17.6)  45 (16.4) 
Delayed interval debulking surgery 
Weeks from NACT last cycle to surgery 
    
Median (range)  4.1 (2.4-6.9) 4.1 (1.6-6.3) 4.0 (1.7-6.1) 4.1 (1.6-6.9) 
Presence of disease at end of surgery  40 (39.6)  30 (41.7)  37 (36.3)  107 (38.9) 
Days from surgery to randomization     
0 (peroperative)  78 (77.2)  58 (80.6)  78 (76.5)  214 (72.8) 
1-7  4   (4.0)  0   (0.0)  1   (1.0)  5   (1.8) 
8-14 
≥ 15 
 1   (1.0) 
 18 (17.8) 
 1   (1.4) 
 13 (18.1) 
 2   (2.0) 
 21 (10.6) 
 4   (1.5) 
 52 (18.9) 
Days from surgery to day 1 of cycle 1     
Median (range)  28 (5-50)  32 (7-56)  32 (7-51)  31 (5-56) 
     
Data are number (percentage) unless otherwise specified  
IP=intraperitoneal; IV=intravenous; NA- not applicable; NACT=neoadjuvant chemotherapy 
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Table 2:  Progression Events (ITT analysis) 
 
 Arm 1 (N=101) 
IV carboplatin 
 + IV  paclitaxel 
Arm 2 (N=72) 
IP cisplatin  
+ IV/IP paclitaxel 
Arm 3 (N=102) 
IP carboplatin 
 + IV/IP 
paclitaxel 
Crude differences 
in cumulative 
incidence  
of PD9 
N % (95%CI) N % (95%CI) N % (95%CI) % (95%CI) 
Progression or death at or before 
Month 9 
39 38.6  
(29.1- 48.1) 
25 34.7 
 (23.7- 45.7) 
2
5 
24.5  
(16.2 -32.9) 
 
Arm 1 versus Arm 3       14.1  (1.5-26.7) 
Arm 2 versus Arm 3       10.2 (-3.6-24.0) 
Time of event        
First relapse/Progression on 
treatment 
0  1  0   
Objective progression only 0  0  0   
CA125 progression only 0  0  0   
Both objective and CA125 
progressions 
0  1  0   
First relapse/Progression during 
follow-up 
39  24  2
4 
  
Objective progression only 17  5  7   
CA125 progression only 0  0  0   
Both objective and CA125 
progressions 
22  19  1
7 
  
Death (without 
relapse/progression) 
0  0  1   
IP=intraperitoneal; IV=intravenous 
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Figure 1: OV21/PETROC Flow Diagram 
 
Arm 3 
IP carboplatin + IV/IP 
paclitaxel 
102 randomized (ITT 
population) 
 92 treated  
 10 never treated 
2 withdrew consent 
0 lost to follow-up 
  
Arm 1 
IV carboplatin + IV paclitaxel 
101 randomized (ITT 
population) 
95 treated 
6 never treated 
4 withdrew consent 
1 lost to follow-up 

275 Randomized 
Arm 2 
IP cisplatin + IV/IP paclitaxel 
72 randomized (ITT 
population) * 
 67 treated  
 5 never treated 
 4 withdrew consent 
 0 lost to follow-up 
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Figure 2: PFS Arm 1: IV carboplatin + IV paclitaxel; Arm 2: IP cisplatin + IV/IP 
paclitaxel; Arm 3: IP carboplatin + IV/IP paclitaxel 
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(b) 
Figure 3: Overall Survival - Arm 1: IV carboplatin + IV paclitaxel; Arm 2: IP 
cisplatin + IV/IP paclitaxel; Arm 3: IP carboplatin + IV/IP paclitaxel 
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